SCHEMBL3597122

SCHEMBL3597122

CC(C)(C)OC(=O)N1CCN2C(=O)N(c3cccc(N)c3)CC2C1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.64
SCN9A Q15858 2/20 0.48
GPR119 Q8TDV5 3/20 0.44
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43
NR1H2 P55055 3/20 0.42
EGFR P00533 3/20 0.39
SRC P12931 3/20 0.39
ABL1 P00519 2/20 0.39
ABL2 P42684 2/20 0.39
FPR2 P25090 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
NR1H3 Q13133 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605594 0.89 USP30 (0.61) USP30SCN9AGPR119MAPT
SCHEMBL3601053 0.89 USP30 (0.61) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3606728 0.89 USP30 (0.61) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3609982 0.88 USP30 (0.60) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3601849 0.88 USP30 (0.60) USP30SCN9AGPR119EGFRSRC
SCHEMBL3606117 0.88 USP30 (0.60) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3604813 0.88 USP30 (0.59) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3607456 0.88 USP30 (0.59) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3601993 0.88 USP30 (0.59) USP30SCN9AGPR119SMARCA2SMARCA4
SCHEMBL3609565 0.88 USP30 (0.62) USP30SCN9AGPR119SMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A USP30 4815/4885SCN9A 1132/4885GPR119 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.